secwatch.observer — SEC 8-K summary
======================================

Issuer:     LABCORP HOLDINGS INC. (LH)
CIK:        0000920148
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0000920148-25-000093
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Labcorp Q3 adjusted EPS $4.18 vs $3.50; raises FY adjusted EPS midpoint to $16.15-$16.50
--------------------------------------------------------------------------------

- Revenue $3.56B (+8.6% YoY); diluted EPS $3.12 (vs $2.00); adjusted EPS $4.18 (vs $3.50).
- Full-year guidance: revenue growth 7.4%-8.0% (midpoint lowered 40 bps), adjusted EPS $16.15-$16.50 (midpoint +$0.05).
- Free cash flow 9M 2025 $715.7M; FY guidance raised to $1.17B-$1.29B.
- Acquired oncology assets from BioReference, signed deals with Empire City Labs, Laboratory Alliance, and Crouse Health.
- Quarterly dividend $0.72/share payable Dec 11, 2025; repurchased $25M stock in Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/920148/000092014825000093/0000920148-25-000093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/920148/000092014825000093/lh-20251028.htm
  HTML page:      https://secwatch.observer/filing/0000920148-25-000093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer